Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1,3,8-trihydroxy-2-(3-methoxyphenyl)-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-2-(4-methoxyphenyl)-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-2-iodo-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-(3-methylphenyl)anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-(pyridin-3-yl)anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-phenylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-[(morpholin-4-yl)methyl]anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-[(piperidin-1-yl)methyl]anthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methyl-2-[[methyl(phenyl)amino]methyl]anthracene-9,10-dione
-
-
1,3-dibromo-2,4,5-trihydroxy-7-methylanthracene-9,10-dione
-
-
1-chloro-2,4,5-trihydroxy-7-methylanthracene-9,10-dione
-
-
2,4,5-trihydroxy-7-methyl-1,3-di(pyridin-3-yl)anthracene-9,10-dione
-
-
2-chloro-1,3,8-trihydroxy-6-methylanthracen-9(10H)-one
-
-
2-chloro-1,3,8-trihydroxy-6-methylanthracene-9,10-dione
-
-
3-(1,3-benzoxazol-5-yl)-5,7-dihydroxy-9-methyl-3,4-dihydro-2H-anthra[2,3-e][1,3]oxazine-6,11-dione
-
-
4-chloro-1,3,8-trihydroxy-6-methylanthracen-9(10H)-one
-
-
4-[[(2-hexyl-6-oxo-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-3-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 95% inhibition. 0.1 mM, 100% inhibition
-
4-[[(3,4-dibenzyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 3% inhibition. 0.1 mM, 64% inhibition
-
4-[[(3,4-dibenzyl-6-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 32% inhibition. 0.1 mM, 84% inhibition
-
4-[[(6-hexyl-2-oxo-4-phenyl-2H-1-benzopyran-7-yl)oxy]methyl]-5-methylfuran-2-carboxylic acid
0.01 mM, 53% inhibition. 0.1 mM, 92% inhibition
-
5,7-dihydroxy-9-methyl-3-phenyl-3,4-dihydro-2H-anthra[2,3-e][1,3]oxazine-6,11-dione
-
5-methyl-4-[[(2-oxo-4-phenyl-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM,32% inhibition. 0.1 mM, 84% inhibition
-
5-methyl-4-[[(2-oxo-4-phenyl-6-propyl-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 97% inhibition. 0.1 mM, 97% inhibition
-
5-methyl-4-[[(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 45% inhibition. 0.1 mM, 101% inhibition
-
5-methyl-4-[[(4-methyl-6-oxo-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-3-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 17% inhibition. 0.1 mM, 90% inhibition
-
5-[(2,3-dimethylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 11% inhibition. 0.1 mM, 43% inhibition
-
5-[(4-fluoro-2-methylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 3% inhibition. 0.1 mM, 9% inhibition
-
5-[(4-fluorobenzene-1-sulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM, 19% inhibition. 0.1 mM, 70% inhibition
-
5-[(4-methyl-3-nitrobenzene-1-sulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM,21% inhibition. 0.1 mM, 89% inhibition
-
5-[(4-methylbenzene-1-sulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM, 23% inhibition. 0.1 mM, 93% inhibition
-
5-[(benzenesulfonyl)amino]-2-phenyl-1-benzofuran-3-carboxylic acid
0.01 mM, 11% inhibition. 0.1 mM, 56% inhibition
-
5-[[(3,4-dibenzyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 9% inhibition. 0.1 mM, 49% inhibition
-
5-[[(4-methyl-6-oxo-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-3-yl)oxy]methyl]furan-2-carboxylic acid
0.01 mM, 18% inhibition. 0.1 mM, 88% inhibition
-
6,7-dibenzyl-2-methyl-5-[(4-methylbenzene-1-sulfonyl)amino]-1-benzofuran-3-carboxylic acid
0.01 mM, 12% inhibition. 0.1 mM, 42% inhibition
-
6,7-dibenzyl-5-[(4-ethylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 42% inhibition. 0.1 mM, 97% inhibition
-
6,7-dibenzyl-5-[(4-fluorobenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 28% inhibition. 0.1 mM, 95% inhibition
-
6,7-dibenzyl-5-[(4-tert-butylbenzene-1-sulfonyl)amino]-2-methyl-1-benzofuran-3-carboxylic acid
0.01 mM, 16% inhibition. 0.1 mM, 59% inhibition
-
methyl 3-chloro-5-(N-(4,6-difluoro-[1,1'-biphenyl]-3-yl)sulfamoyl)-4-hydroxybenzoate
SB-204990
in addition to lowering lipids by inhibiting ACLY, the chemical inhibitor SB-204990 also displays tumor suppressive effects
(+)-2,2-difluorocitrate
-
-
(-)-2,2-difluorocitrate
-
-
(-)-Hydroxycitrate
-
potent inhibitor
(1S,2S)-1,2-dihydroxypropane-1,2,3-tricarboxylic acid
-
50% inhibition at 0.00015 mM
(2E)-3-phenylprop-2-en-1-yl 2-[[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]amino]benzoate
-
50% inhibition at 0.00034 mM
(2R)-2-[(2S)-8-(3,5-dichlorophenyl)-2-hydroxyoctyl]-2-hydroxysuccinic acid
-
50% inhibition at 0.0021 mM
3,5-dichloro-2-hydroxy-N-(4-methoxybiphenyl-3-yl)benzenesulfonamide
-
50% inhibition of enzyme at 0.00013 mM, 50% inhibition of total lipid synthesis in HepG-2 cells at 0.008 mM, no cytotoxicity up to 0.05 mM
3,5-dichloro-N-(2,4,6-triphenyl-phenyl)-2-hydroxybenzenesulfonamide
-
50% inhibition at 0.00019 mM
3,5-dichloro-N-(3,5-di-tert-butylphenyl)-2-hydroxybenzenesulfonamide
-
50% inhibition at 0.0011 mM
5-methyl-2-(1-methylethyl)cyclohexyl 2-[[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]amino]benzoate
-
50% inhibition at 0.00037 mM
diethyldicarbonate
-
the addition of 0.5 mM ATP in the preincubation reaction mixture provided complete protection of enzyme activity from inactivation by diethyldicarbonate
radicicol
-
noncompetitive inhibitor
bempedoic acid
-
bempedoic acid
i.e. ETC-1002 is a first-in-class, prodrug-based direct competitive inhibitor of ATP citrate lyase which regulates lipid metabolism by upregulating hepatic LDL receptor (LDLr) expression and activity. Pharmacological inhibition of ACLY by bempedoic acid, prevents dyslipidemia and attenuates atherosclerosis in hypercholesterolemic ApoE-/- mice, LDLr-/- mice, and LDLr-/- miniature pigs
methyl 3-chloro-5-(N-(4,6-difluoro-[1,1'-biphenyl]-3-yl)sulfamoyl)-4-hydroxybenzoate
i.e. NDI-091143, allosteric inhibition
methyl 3-chloro-5-(N-(4,6-difluoro-[1,1'-biphenyl]-3-yl)sulfamoyl)-4-hydroxybenzoate
i.e. NDI-091143, the structure of the full-length human ACLY homo-tetramer in complex NDI-091143 is determined by cryo-electron microscopy. The compound is located in an allosteric, mostly hydrophobic cavity next to the citrate-binding site, and requires extensive conformational changes in the enzyme that indirectly disrupt citrate binding
Tartrate
-
Hydroxycitrate
-
Hydroxycitrate
-
competitive
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
Adenosine triphosphate citrate lyase mediates hypocitraturia in rats.
Acidosis
Converting enzyme inhibition causes hypocitraturia independent of acidosis or hypokalemia.
Adenocarcinoma
ATP citrate lyase expression is associated with advanced stage and prognosis in gastric adenocarcinoma.
Alzheimer Disease
Coenzyme A-acetylating enzymes in Alzheimer's disease: possible cholinergic 'compartment' of pyruvate dehydrogenase.
Ataxia Telangiectasia
Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination.
Atherosclerosis
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
Atherosclerosis
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
Atherosclerosis
New Era of Lipid-Lowering Drugs.
Atherosclerosis
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr(-/-) Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.
Atherosclerosis
Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
atp citrate synthase deficiency
ATP-citrate lyase deficiency in the mouse.
atp citrate synthase deficiency
Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques.
Brain Diseases
[NADP malate dehydrogenase, acetyl-CoA synthetase and ATP citrate lyase in experimental cyanide encephalopathy]
Breast Neoplasms
ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis.
Breast Neoplasms
Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells.
Breast Neoplasms
Hydroxycitric acid potentiates the cytotoxic effect of tamoxifen in MCF-7 breast cancer cells through inhibition of ATP citrate lyase.
Breast Neoplasms
Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast.
Breast Neoplasms
MiR-22 down-regulates the proto-oncogene ATP citrate lyase to inhibit the growth and metastasis of breast cancer.
Breast Neoplasms
mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.
Carcinogenesis
A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results.
Carcinogenesis
Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis.
Carcinoma
Overexpression of ATP citrate lyase in renal cell carcinoma tissues and its effect on the human renal carcinoma cells in vitro.
Carcinoma, Hepatocellular
ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2?/ATF4/CHOP axis.
Carcinoma, Hepatocellular
ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/?-catenin signaling pathway.
Carcinoma, Hepatocellular
GTP, a nonsubstrate of ATP citrate lyase, is a phosphodonor for the enzyme histidine autophosphorylation.
Carcinoma, Non-Small-Cell Lung
ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly.
Carcinoma, Non-Small-Cell Lung
Spermidine reduces cancer-related mortality in humans.
Carcinoma, Ovarian Epithelial
Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer.
Carcinoma, Renal Cell
Overexpression of ATP citrate lyase in renal cell carcinoma tissues and its effect on the human renal carcinoma cells in vitro.
Carcinoma, Renal Cell
Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression.
Cardiovascular Diseases
Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis.
Cardiovascular Diseases
Mendelian Randomization Study of ACLY and Cardiovascular Disease.
Colonic Neoplasms
ACLY facilitates colon cancer cell metastasis by CTNNB1.
Colonic Neoplasms
Biological Behavior and Lipid Metabolism of Colon Cancer Cells are Regulated by a Combination of Sterol Regulatory Element-Binding Protein 1 and ATP Citrate Lyase.
Colorectal Neoplasms
ATP citrate lyase mediates resistance of colorectal cancer cells to SN38.
Colorectal Neoplasms
Biological Behavior and Lipid Metabolism of Colon Cancer Cells are Regulated by a Combination of Sterol Regulatory Element-Binding Protein 1 and ATP Citrate Lyase.
Colorectal Neoplasms
Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer.
Diabetes Mellitus
The role of adenosine triphosphate citrate lyase in the metabolism of acetyl coenzyme a and function of blood platelets in diabetes mellitus.
Diabetes Mellitus, Type 2
Lower succinyl-CoA:3-ketoacid-CoA transferase (SCOT) and ATP citrate lyase in pancreatic islets of a rat model of type 2 diabetes: knockdown of SCOT inhibits insulin release in rat insulinoma cells.
Dyslipidemias
Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia.
Dyslipidemias
ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
Fatty Liver
Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Fatty Liver
Some lipogenic enzyme activities in rat livers in which an excessive fat accumulation occurred due to feeding low-level amino acid mixture diets.
Glioblastoma
Acetyl-CoA promotes glioblastoma cell adhesion and migration through Ca2+-NFAT signaling.
Glioblastoma
Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas.
Glioma
Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.
Hepatitis B
Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis.
Hypercholesterolemia
Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Hypercholesterolemia
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Hypercholesterolemia
Measurement of bempedoic acid and its keto metabolite in human plasma and urine using solid phase extraction and electrospray LC-MS/MS.
Hypercholesterolemia
Phytochemical and biological studies on rare and endangered plants endemic to China. Part XV. Structurally diverse diterpenoids and sesquiterpenoids from the vulnerable conifer Pseudotsuga sinensis.
Hyperglycemia
Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Hyperglycemia
Effects of high sucrose diet on insulin-like effects of vanadate in diabetic rats.
Hyperinsulinism
Chronic hyperinsulinemia in the fetal rhesus monkey: effects of physiologic hyperinsulinemia on fetal substrates, hormones, and hepatic enzymes.
Hyperinsulinism
Chronic hyperinsulinemia in the fetal rhesus monkey: effects on hepatic enzymes active in lipogenesis and carbohydrate metabolism.
Hyperlipidemias
Docking study of novel antihyperlipidemic thieno[2,3-d]pyrimidine; LM-1554, with some molecular targets related to hyperlipidemia - an investigation into its mechanism of action.
Hyperlipidemias
Forrestiacids?A and?B, Pentaterpene Inhibitors of ACL and Lipogenesis: Extending the Limits of Computational NMR Methods in the Structure Assignment of Complex Natural Products.
Hyperlipidemias
Phytochemical and biological studies on rare and endangered plants endemic to China. Part XV. Structurally diverse diterpenoids and sesquiterpenoids from the vulnerable conifer Pseudotsuga sinensis.
Hyperlipidemias
Targeting ATP-Citrate Lyase in Hyperlipidemia and Metabolic Disorders.
Hypokalemia
Adenosine triphosphate citrate lyase mediates hypocitraturia in rats.
Hypokalemia
Converting enzyme inhibition causes hypocitraturia independent of acidosis or hypokalemia.
Hypothyroidism
A tissue-specific increase in lipogenesis in rat brown adipose tissue in hypothyroidism.
Insulin Resistance
Changes in lipid synthesis in rat adipose tissue during development.
Insulin Resistance
Pyruvate dehydrogenase and ATP citrate (pro-3S)-lyase activities in adipose tissue and liver of the young lean and the older obese rat.
Insulinoma
Lower succinyl-CoA:3-ketoacid-CoA transferase (SCOT) and ATP citrate lyase in pancreatic islets of a rat model of type 2 diabetes: knockdown of SCOT inhibits insulin release in rat insulinoma cells.
Leukemia
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Leukemia, Myeloid, Acute
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Liver Diseases
ATP Citrate Lyase and LncRNA NONMMUT010685 Play Crucial Role in Nonalcoholic Fatty Liver Disease Based on Analysis of Microarray Data.
Liver Diseases
Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
Liver Diseases
In Steatotic Cells, ATP-Citrate Lyase mRNA Is Efficiently Translated through a Cap-Independent Mechanism, Contributing to the Stimulation of De Novo Lipogenesis.
Liver Diseases
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Liver Diseases, Alcoholic
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Liver Neoplasms
Aberrant lipid metabolism as a therapeutic target in liver cancer.
Lung Neoplasms
ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
Lung Neoplasms
Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.
Lung Neoplasms
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways.
Lung Neoplasms
miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Lung Neoplasms
Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer.
Lung Neoplasms
Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly.
Lung Neoplasms
Spermidine reduces cancer-related mortality in humans.
Melanoma
ATP-citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition.
Melanoma
Cinerols, Nitrogenous Meroterpenoids from the Marine Sponge Dysidea cinerea.
Melanoma
Identification of potential diagnostic and prognostic biomarkers for prostate cancer.
Myocardial Infarction
Weighted gene co?expression network analysis in identification of key genes and networks for ischemic?reperfusion remodeling myocardium.
Nasopharyngeal Carcinoma
ER resident protein 44 promotes malignant phenotype in nasopharyngeal carcinoma through the interaction with ATP citrate lyase.
Neoplasm Metastasis
ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/?-catenin signaling pathway.
Neoplasm Metastasis
Clinical-translational approaches to the Nm23-H1 metastasis suppressor.
Neoplasm Metastasis
IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R.
Neoplasm Metastasis
MiR-22 down-regulates the proto-oncogene ATP citrate lyase to inhibit the growth and metastasis of breast cancer.
Neoplasm Metastasis
miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Neoplasms
A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results.
Neoplasms
Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis.
Neoplasms
Acetylation Stabilizes ATP-Citrate Lyase to Promote Lipid Biosynthesis and Tumor Growth.
Neoplasms
ACLY and ACC1 Regulate Hypoxia-Induced Apoptosis by Modulating ETV4 via ?-ketoglutarate.
Neoplasms
ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia.
Neoplasms
Adding a combination of hydroxycitrate and lipoic acid (METABLOC) to chemotherapy improves effectiveness against tumor development: experimental results and case report.
Neoplasms
Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.
Neoplasms
ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment.
Neoplasms
ATP citrate lyase inhibition can suppress tumor cell growth.
Neoplasms
ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2?/ATF4/CHOP axis.
Neoplasms
ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents.
Neoplasms
ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis.
Neoplasms
ATP citrate lyase knockdown impacts cancer stem cells in vitro.
Neoplasms
ATP citrate lyase: A central metabolic enzyme in cancer.
Neoplasms
ATP-citrate lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition.
Neoplasms
ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/?-catenin signaling pathway.
Neoplasms
ATP-Citrate Lyase: A Key Player in Cancer Metabolism.
Neoplasms
Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.
Neoplasms
Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression.
Neoplasms
Cytoplasmic Citrate Flux Modulates the Immune Stimulatory NKG2D Ligand MICA in Cancer Cells.
Neoplasms
Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer.
Neoplasms
Differentiation of human tumors from nonmalignant tissue by natural-abundance 13C NMR spectroscopy.
Neoplasms
Epistructured catechins, EGCG and EC facilitate apoptosis induction through targeting de novo lipogenesis pathway in HepG2 cells.
Neoplasms
Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer.
Neoplasms
Human adipocyte differentiation and composition of disease-relevant lipids are regulated by miR-221-3p.
Neoplasms
Hydroxycitrate causes altered pyruvate metabolism by tumorigenic cells.
Neoplasms
Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth.
Neoplasms
Increased lipogenesis in cancer cells: new players, novel targets.
Neoplasms
Inhibition of ATP Citrate Lyase Induces an Anticancer Effect via Reactive Oxygen Species: AMPK as a Predictive Biomarker for Therapeutic Impact.
Neoplasms
Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
Neoplasms
Inhibition of Fatty Acid Synthase Attenuates CD44-Associated Signaling and Reduces Metastasis in Colorectal Cancer.
Neoplasms
Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4.
Neoplasms
Leelamine is a Novel Lipogenesis Inhibitor in Prostate Cancer Cells In Vitro and In Vivo.
Neoplasms
Liver fat content and lipid metabolism in dairy cows during early lactation and during a mid-lactation feed restriction.
Neoplasms
Mendelian Randomization Study of ACLY and Cardiovascular Disease.
Neoplasms
miR-133b acts as a tumor suppressor and negatively regulates ATP citrate lyase via PPAR? in gastric cancer.
Neoplasms
miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Neoplasms
Myeloid-Specific Acly Deletion Alters Macrophage Phenotype In Vitro and In Vivo without Affecting Tumor Growth.
Neoplasms
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Neoplasms
Pharmacological induction of mesenchymal-epithelial transition via inhibition of H2S biosynthesis and consequent suppression of ACLY activity in colon cancer cells.
Neoplasms
Polyamine regulating protein antizyme binds to ATP citrate lyase to accelerate acetyl-CoA production in cancer cells.
Neoplasms
Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer.
Neoplasms
Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly.
Neoplasms
Resveratrol prevents hepatic steatosis and endoplasmic reticulum stress and regulates the expression of genes involved in lipid metabolism, insulin resistance, and inflammation in rats.
Neoplasms
Retraction note to: decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer.
Neoplasms
Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer.
Neoplasms
Systematic integration of molecular profiles identifies miR-22 as a regulator of lipid and folate metabolism in breast cancer cells.
Neoplasms
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.
Neoplasms
Targeting Mitochondrial Citrate Transport in Breast Cancer Cell Lines.
Neoplasms
The metabolic advantage of tumor cells.
Neoplasms
The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis.
Neoplasms
Weighted gene co?expression network analysis in identification of key genes and networks for ischemic?reperfusion remodeling myocardium.
Neuroblastoma
The enzymes of acetyl-CoA metabolism in differentiating cholinergic (s-20) and noncholinergic (NIE-115) neuroblastoma cells.
Non-alcoholic Fatty Liver Disease
ATP Citrate Lyase and LncRNA NONMMUT010685 Play Crucial Role in Nonalcoholic Fatty Liver Disease Based on Analysis of Microarray Data.
Non-alcoholic Fatty Liver Disease
Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Obesity
Changes in hepatic lipogenic enzyme activities in voles and mice treated with monosodium aspartate.
Obesity
Effects of garcinia cambogia (Hydroxycitric Acid) on visceral fat accumulation: a double-blind, randomized, placebo-controlled trial.
Obesity
The impact of hydroxycitric acid on the lipid metabolism profile under experimental insulin resistance syndrome of Syrian hamsters.
Osteosarcoma
miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Ovarian Neoplasms
Regulation of protein metabolism in cancer.
Ovarian Neoplasms
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.
Overweight
ATP-citrate lyase is an epigenetic regulator to promote obesity-related kidney injury.
Overweight
Lipogenic gene expression in abdominal adipose and liver tissues of diet-induced overweight cats.
Pancreatic Neoplasms
Decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer.
Pancreatic Neoplasms
Retraction note to: decreased Warburg effect induced by ATP citrate lyase suppression inhibits tumor growth in pancreatic cancer.
Prostatic Neoplasms
Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate lyase signaling.
Prostatic Neoplasms
Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth.
Prostatic Neoplasms
miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Prostatic Neoplasms
Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism.
Prostatic Neoplasms
Retraction: Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate lyase signaling.
Prostatic Neoplasms
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.
Sepsis
Serum proteome-wide identified ATP citrate lyase as a novel informative diagnostic and prognostic biomarker in pediatric sepsis: A pilot study.
Starvation
Age-dependent hepatic lipogenic enzyme activities in starved-refed rats.
Starvation
Engineering cytoplasmic acetyl-CoA synthesis decouples lipid production from nitrogen starvation in the oleaginous yeast Rhodosporidium azoricum.
Stomach Neoplasms
miR-133b acts as a tumor suppressor and negatively regulates ATP citrate lyase via PPAR? in gastric cancer.
Uterine Cervical Neoplasms
miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.
Vitamin B 6 Deficiency
Effects of vitamin B6 deficiency on liver, kidney, and adipose tissue enzymes associated with carbohydrate and lipid metabolism, and on glucose uptake by rat epididymal adipose tissue.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
evolution
structural studies unmask a fundamental evolutionary relationship that links citrate synthase, the first enzyme of the oxidative Krebs cycle, to an ancestral tetrameric citryl-CoA lyase module that operates in the reverse Krebs cycle. This molecular transition marked a key step in the evolution of metabolism on Earth
physiological function
ATP citrate lyase plays a key role in regulating mitochondrial function, as well as glucose and lipid metabolism in skeletal muscle. The enzyme increases myoblast and satellite cell differentiation in vitro. It increases MYOD expression by acetyl-H3(K9/14/27) enrichment at the MYOD promoter. It acts downstream of IGF-1 to stimulate myogenesis. IT improves muscle regeneration following cardiotoxin-induced injury
malfunction
ATP citrate lyase silencing impairs myoblast and satellite cell differentiation, and it is accompanied by a decrease in fast myosin heavy chain isoforms and MYOD
malfunction
siRNA knockdown of ATP citrate lyase limits cancer cell proliferation and reduces cancer stemness
metabolism
acetyl-coenzyme A (acetyl-CoA) generated by ATP citrate lyase (ACL) is utilized to acetylate histone H3 at MyoD regulatory regions, resulting in increased MyoD expression and improved muscle regeneration after injury
metabolism
ATP citrate lyase is an important enzyme linking carbohydrate to lipid metabolism by generating acetyl-CoA from citrate for fatty acid and cholesterol biosynthesis
metabolism
ATP-citrate lyase is a central metabolic enzyme. The acetyl-CoA product is crucial for the metabolism of fatty acids, the biosynthesis of cholesterol, and the acetylation and prenylation of proteins
metabolism
enzyme in the de novo lipogenesis pathway. The enzyme is required for low molecular weight cyclin E-mediated transformation, migration, and invasion of breast cancer cells in vitro along with tumor growth in vivo
metabolism
modulation of ACLY expression correlates with the development and progressions of various chronic diseases such as neurodegenerative diseases, cardiovascular diseases, diabetes, obesity, inflammation, and cancer. Inhibition of ACLY activity modulates the glycolysis and lipogenesis processes and stimulates normal physiological functions
metabolism
regulatory role of ACLY activity in chondrocyte matrix homeostasis by modulation of the nucleocytosolic pool of acetyl-CoA, which impacted on catabolic and anabolic responses via post-translational and epigenetic modifications. Increased ACLY activity in osteoarthritis chondrocytes increases nucleocytosolic acetyl-CoA, leading to increased matrix catabolism via dysregulated histone and transcription factor acetylation
metabolism
the enzyme catalyzes the formation of cytosolic acetyl CoA, the starting material for de novo lipid and cholesterol biosynthesis
metabolism
the enzyme is a major source of nucleocytosolic acetyl-CoA, a fundamental building block of carbon metabolism in eukaryotes
metabolism
the enzyme is an epigenetic regulator that promotes renal ectopic lipid accumulation and fibrogenesis leading to renal injury in obesity. Induction of ATP-citrate lyase in in the kidney of overweight or obese patients with chronic kidney disease is associated with increased ectopic lipid accumulation, glomerulosclerosis, and albuminuria. Acetyl-CoA is the substrate for de novo lipogenesis as well as for histone acetylation. By raising acetyl-CoA concentration ATP-citrate lyase promotes H3K9/14 and H3K27 hyperacetylation leading to up-regulation of several rate-limiting lipogenic enzymes and fibrogenic factors. On the other hand, the excess acetyl-CoA generated as a result of ATP-citrate lyase induction provides the substrate for these lipogenic enzymes to drive de novo lipogenesis leading to ectopic lipid accumulation, a detrimental event toward renal injury
metabolism
the enzyme links carbohydrate and lipid metabolism
metabolism
the enzyme links energy metabolism provided by catabolic pathways to biosynthesis. ACLY plays a pivotal role in cancer metabolism through the potential deprivation of cytosolic citrate, a process promoting glycolysis through the enhancement of the activities of PFK 1 and 2 with concomitant activation of oncogenic drivers such as PI3K/AKT which activate ACLY and the Warburg effect in a feed-back loop
metabolism
the enzyme plays a critical role in generating cytosolic acetyl CoA, a key building block for de novo fatty acid and cholesterol biosynthesis
metabolism
the enzyme synthesizes cytosolic acetyl coenzyme A (acetyl-CoA), a fundamental cellular building block
malfunction
-
ATP citrate lyase knockdown induces proliferation arrest, cell-cycle arrest, and apoptosis in cancer cells and results in elevated expression of acyl-CoA synthetase short-chain family member 2
malfunction
inhibition of the enzyme suppresses in vitro glioblastoma cell migration, clonogenicity and brain invasion under glycolytic conditions and enhances the suppressive effects of a Met inhibitor on cell migration
malfunction
-
overexpression of the enzyme is observed in nonalcoholic fatty liver disease. Increased enzyme activity is associated with hypocituria, nonalcoholic fatty liver disease, and tumor cell growth. Decreased enzyme activity is associated with type 2 diabetes. ACLY knockdown or inhibition leads to a decrease in glucose-induced insulin secretion
malfunction
-
enzyme activity inhibition as well as gene silencing lead to reduced nitric oxide, reactive oxygen species and prostaglandin E2 inflammatory mediators
malfunction
-
enzyme knockdown triggers cellular senescence and activation of tumor suppressor p53
metabolism
-
involved in lung cancer pathogenesis
metabolism
-
the enzyme is involved in citrate metabolism
physiological function
ATP citrate lyase is a positive regulator of glycolytic function in glioblastomas
physiological function
-
the enzyme is essential for macrophage inflammatory response
physiological function
-
the enzyme regulates cellular senescence via an AMPK- and p53-dependent pathway
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Hoffmann, G.E.; Andres, H.; Weiss, L.; Kreisel, C.; Sander, R.
Properties and organ distribution of ATP citrate (pro-3S)-lyase
Biochim. Biophys. Acta
620
151-158
1980
Gallus gallus, Homo sapiens, Rattus norvegicus
brenda
Tosukhowong, P.; Borvonpadungkitti, S.; Prasongwatana, V.; Tungsanga, K.; Jutuporn, S.; Dissayabutr, T.; Reungjui, S.; Sriboonlue, P.
Urinary citrate excretion in patients with renal stone: roles of leucocyte ATP citrate lyase activity and potassium salts therapy
Clin. Chim. Acta
325
71-78
2002
Homo sapiens
brenda
Ki, S.W.; Ishigami, K.; Kitahara, T.; Kasahara, K.; Yoshida, M.; Horinouchi, S.
Radicicol binds and inhibits mammalian ATP citrate lyase
J. Biol. Chem.
275
39231-39236
2000
Homo sapiens, Rattus norvegicus
brenda
Potapova, I.A.; El-Maghrabi, M.R.; Doronin, S.V.; Benjamin, W.B.
Phosphorylation of recombinant human ATP:citrate lyase by cAMP-dependent protein kinase abolishes homotropic allosteric regulation of the enzyme by citrate and increases the enzyme activity. Allosteric activation of ATP:citrate lyase by phosphorylated sugars
Biochemistry
39
1169-1179
2000
Homo sapiens, Rattus norvegicus
brenda
Tosukhowong, P.; Tungsanga, K.; Phongudom, S.; Sriboonlue, P.
Effects of potassium-magnesium citrate supplementation on cytosolic ATP citrate lyase and mitochondrial aconitase activity in leukocytes: a window on renal citrate metabolism
Int. J. Urol.
12
140-144
2005
Homo sapiens
brenda
Michno, A.; Skibowska, A.; Raszeja-Specht, A.; Cwikowska, J.; Szutowicz, A.
The role of adenosine triphosphate citrate lyase in the metabolism of acetyl coenzyme a and function of blood platelets in diabetes mellitus
Metabolism
53
66-72
2004
Homo sapiens
brenda
Li, J.J.; Wang, H.; Tino, J.A.; Robl, J.A.; Herpin, T.F.; Lawrence, R.M.; Biller, S.; Jamil, H.; Ponticiello, R.; Chen, L.; Chu, C.H.; Flynn, N.; Cheng, D.; Zhao, R.; Chen, B.; Schnur, D.; Obermeier, M.T.; Sasseville, V.; Padmanabha, R.; Pike, K.; Harrity, T.
2-Hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors
Bioorg. Med. Chem. Lett.
17
3208-3211
2007
Homo sapiens, Mus musculus
brenda
Hatzivassiliou, G.; Zhao, F.; Bauer, D.E.; Andreadis, C.; Shaw, A.N.; Dhanak, D.; Hingorani, S.R.; Tuveson, D.A.; Thompson, C.B.
ATP citrate lyase inhibition can suppress tumor cell growth
Cancer Cell
8
311-321
2005
Homo sapiens, Mus musculus
brenda
Migita, T.; Narita, T.; Nomura, K.; Miyagi, E.; Inazuka, F.; Matsuura, M.; Ushijima, M.; Mashima, T.; Seimiya, H.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y.
ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer
Cancer Res.
68
8547-8554
2008
Homo sapiens
brenda
Beckner, M.E.; Fellows-Mayle, W.; Zhang, Z.; Agostino, N.R.; Kant, J.A.; Day, B.W.; Pollack, I.F.
Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas
Int. J. Cancer
126
2282-2295
2009
Homo sapiens, Homo sapiens (P53396)
brenda
Ma, Z.; Chu, C.; Cheng, D.
A novel direct homogeneous assay for ATP citrate lyase
J. Lipid Res.
50
2131-2135
2009
Homo sapiens
brenda
Wellen, K.; Hatzivassiliou, G.; Sachdeva, U.; Bui, T.; Cross, J.; Thompson, C.
ATP-citrate lyase links cellular metabolism to histone acetylation
Science
324
1076-1080
2009
Homo sapiens
brenda
Sun, T.; Hayakawa, K.; Fraser, M.E.
ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate lyase
Acta Crystallogr. Sect. F
67
1168-1172
2011
Homo sapiens (P53396), Homo sapiens
brenda
Chypre, M.; Zaidi, N.; Smans, K.
ATP-citrate lyase: a mini-review
Biochem. Biophys. Res. Commun.
422
1-4
2012
Homo sapiens, Mus musculus
brenda
Fan, F.; Williams, H.J.; Boyer, J.G.; Graham, T.L.; Zhao, H.; Lehr, R.; Qi, H.; Schwartz, B.; Raushel, F.M.; Meek, T.D.
On the catalytic mechanism of human ATP citrate lyase
Biochemistry
51
5198-5211
2012
Homo sapiens
brenda
Sun, T.; Hayakawa, K.; Bateman, K.S.; Fraser, M.E.
Identification of the citrate-binding site of human ATP-citrate lyase using X-ray crystallography
J. Biol. Chem.
285
27418-27428
2010
Homo sapiens (P53396), Homo sapiens
brenda
Zaidi, N.; Royaux, I.; Swinnen, J.V.; Smans, K.
ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms
Mol. Cancer Ther.
11
1925-1935
2012
Homo sapiens
brenda
Infantino, V.; Iacobazzi, V.; Palmieri, F.; Menga, A.
ATP-citrate lyase is essential for macrophage inflammatory response
Biochem. Biophys. Res. Commun.
440
105-111
2013
Homo sapiens
brenda
Tajima, A.; Murai, N.; Murakami, Y.; Iwamoto, T.; Migita, T.; Matsufuji, S.
Polyamine regulating protein antizyme binds to ATP citrate lyase to accelerate acetyl-CoA production in cancer cells
Biochem. Biophys. Res. Commun.
471
646-651
2016
Homo sapiens
brenda
Lee, J.H.; Jang, H.; Lee, S.M.; Lee, J.E.; Choi, J.; Kim, T.W.; Cho, E.J.; Youn, H.D.
ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway
FEBS J.
282
361-371
2015
Homo sapiens
brenda
Hu, J.; Komakula, A.; Fraser, M.E.
Binding of hydroxycitrate to human ATP-citrate lyase
Acta Crystallogr. Sect. D
73
660-671
2017
Homo sapiens (P53396), Homo sapiens
brenda
Jernigan, F.E.; Hanai, J.I.; Sukhatme, V.P.; Sun, L.
Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening
Bioorg. Med. Chem. Lett.
27
929-935
2017
Homo sapiens (P53396)
brenda
Icard, P.; Wu, Z.; Fournel, L.; Coquerel, A.; Lincet, H.; Alifano, M.
ATP citrate lyase A central metabolic enzyme in cancer
Cancer Lett.
471
125-134
2020
Homo sapiens (P53396)
brenda
Lucenay, K.S.; Doostan, I.; Karakas, C.; Bui, T.; Ding, Z.; Mills, G.B.; Hunt, K.K.; Keyomarsi, K.
Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells
Cancer Res.
76
2406-2418
2016
Homo sapiens (P53396), Homo sapiens
brenda
Das, S.; Morvan, F.; Morozzi, G.; Jourde, B.; Minetti, G.C.; Kahle, P.; Rivet, H.; Brebbia, P.; Toussaint, G.; Glass, D.J.; Fornaro, M.
ATP citrate lyase regulates myofiber differentiation and increases regeneration by altering histone acetylation
Cell Rep.
21
3003-3011
2017
Homo sapiens (P53396), Mus musculus (Q91V92), Mus musculus
brenda
Koerner, S.K.; Hanai, J.I.; Bai, S.; Jernigan, F.E.; Oki, M.; Komaba, C.; Shuto, E.; Sukhatme, V.P.; Sun, L.
Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase
Eur. J. Med. Chem.
126
920-928
2017
Homo sapiens (P53396)
brenda
Chen, Y.; Deb, D.K.; Fu, X.; Yi, B.; Liang, Y.; Du, J.; He, L.; Li, Y.C.
ATP-citrate lyase is an epigenetic regulator to promote obesity-related kidney injury
FASEB J.
33
9602-9615
2019
Homo sapiens (P53396), Homo sapiens, Mus musculus (Q91V92)
brenda
Chen, L.Y.; Lotz, M.; Terkeltaub, R.; Liu-Bryan, R.
Modulation of matrix metabolism by ATP-citrate lyase in articular chondrocytes
J. Biol. Chem.
293
12259-12270
2018
Homo sapiens (P53396), Homo sapiens
brenda
Bazilevsky, G.A.; Affronti, H.C.; Wei, X.; Campbell, S.L.; Wellen, K.E.; Marmorstein, R.
ATP-citrate lyase multimerization is required for coenzyme-A substrate binding and catalysis
J. Biol. Chem.
294
7259-7268
2019
Homo sapiens (P53396)
brenda
Khwairakpam, A.D.; Banik, K.; Girisa, S.; Shabnam, B.; Shakibaei, M.; Fan, L.; Arfuso, F.; Monisha, J.; Wang, H.; Mao, X.; Sethi, G.; Kunnumakkara, A.B.
The vital role of ATP citrate lyase in chronic diseases
J. Mol. Med.
98
71-95
2020
Homo sapiens (P53396)
brenda
Wei, X.; Schultz, K.; Bazilevsky, G.A.; Vogt, A.; Marmorstein, R.
Molecular basis for acetyl-CoA production by ATP-citrate lyase
Nat. Struct. Mol. Biol.
27
33-41
2020
Homo sapiens (P53396), Homo sapiens
brenda
Wei, J.; Leit, S.; Kuai, J.; Therrien, E.; Rafi, S.; Harwood, H.J.; DeLaBarre, B.; Tong, L.
An allosteric mechanism for potent inhibition of human ATP-citrate lyase
Nature
568
566-570
2019
Homo sapiens (P53396), Homo sapiens
brenda
Verschueren, K.H.G.; Blanchet, C.; Felix, J.; Dansercoer, A.; De Vos, D.; Bloch, Y.; Van Beeumen, J.; Svergun, D.; Gutsche, I.; Savvides, S.N.; Verstraete, K.
Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle
Nature
568
571-575
2019
Homo sapiens (P53396), Homo sapiens, Chlorobium limicola (Q9AQH6)
brenda
Feng, X.; Zhang, L.; Xu, S.; Shen, A.Z.
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis An updated review
Prog. Lipid Res.
77
101006
2020
Homo sapiens (P53396), Homo sapiens
brenda
Li, H.; Sartorelli, V.
ATP citrate lyase a new player linking skeletal muscle metabolism and epigenetics
Trends Endocrinol. Metab.
29
202-204
2018
Homo sapiens (P53396)
brenda
Granchi, C.
Discovery of allosteric inhibition of human ATP-citrate lyase
Trends Pharmacol. Sci.
40
364-366
2019
Homo sapiens (P53396), Homo sapiens
brenda